

Oliver Fitzgerald Mb Bch Bao, Mrcpi, Mrcp, Frcpi,, Frcp

List of Publications by Year in Descending Order

Source:

<https://exaly.com/author-pdf/5557730/oliver-fitzgerald-mb-bch-bao-mrcpi-mrcp-frcpi-frcp-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

257
papers

14,266
citations

61
h-index

111
g-index

301
ext. papers

16,402
ext. citations

5.3
avg, IF

6.25
L-index

#	Paper	IF	Citations
257	Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).. <i>Rheumatology and Therapy</i> , 2022 , 1	4.4	0
256	Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1272-1278	4.1	0
255	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021 , 23, 94	5.7	2
254	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021 ,	4.1	3
253	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e270-e283	14.2	7
252	Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	1
251	5-year longitudinal study of clinical and patient-reported outcomes in acute anterior uveitis. <i>Eye</i> , 2021 , 35, 651-658	4.4	2
250	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?. <i>Arthritis Care and Research</i> , 2021 , 73, 856-860	4.7	17
249	Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211014010	3.8	6
248	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. <i>Journal of Rheumatology</i> , 2021 , 48, 1268-1271	4.1	1
247	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 59	51.1	6
246	Early Origins of Psoriatic Arthritis: Clinical, Genetic and Molecular Biomarkers of Progression From Psoriasis to Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2021 , 8, 723944	4.9	3
245	Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. <i>BMC Musculoskeletal Disorders</i> , 2021 , 22, 817	2.8	1
244	Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	0
243	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020 , 7, 553-580	4.4	29
242	MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesis. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 330-336	5.3	5
241	The many faces of psoriatic arthritis: their genetic determinism. <i>Rheumatology</i> , 2020 , 59, i4-i9	3.9	8

240	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 453-459	2.4	22
239	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020 , 47, 796-808	4.1	1
238	Bristol rheumatoid arthritis fatigue scale is valid in patients with psoriatic arthritis and is associated with overall severe disease and higher comorbidities. <i>Clinical Rheumatology</i> , 2020 , 39, 1851-1858	3.9	1
237	An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. <i>Drug Safety</i> , 2020 , 43, 379-392	5.1	20
236	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. <i>Rheumatology International</i> , 2020 , 40, 1021-1028	3.6	2
235	Elevated CRP even at the first visit to a rheumatologist is associated with long-term poor outcomes in patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020 , 39, 2951-2961	3.9	8
234	Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020 , 96, 19-24	4.1	2
233	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020 , 96, 53-57	4.1	6
232	Advanced musculoskeletal physiotherapy practice: The patient journey and experience. <i>Musculoskeletal Science and Practice</i> , 2020 , 45, 102077	2.4	11
231	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020 , 5, 12-22	1.1	3
230	Cardiovascular Comorbidities in Psoriatic Disease. <i>Rheumatology and Therapy</i> , 2020 , 7, 5-17	4.4	5
229	Applying precision medicine to unmet clinical needs in psoriatic disease. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 609-627	8.1	12
228	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020 , 22, 78	4.9	6
227	Update: Atypical presentation of a midgut neuroendocrine tumor originally diagnosed as eosinophilic fasciitis. <i>Neurology</i> , 2020 , 95, 695-697	6.5	
226	A multidisciplinary approach to reproductive healthcare in women with rheumatic disease. <i>Irish Journal of Medical Science</i> , 2020 , 189, 237-243	1.9	2
225	Effects of 1-year anti-TNF- α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2020 , 39, 167-175	3.9	21
224	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020 , 47, 809-819	4.1	7
223	Physiotherapist-Led Triage at a Rheumatology-Based Musculoskeletal Assessment Clinic: an 18-Month Service Evaluation of Activity and Outcomes. <i>ACR Open Rheumatology</i> , 2019 , 1, 213-218	3.5	1

222	Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1107-1113	2.4	8
221	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , 2019 , 46, 1089-1096	4.1	21
220	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019 , 46, 996-1005	4.1	21
219	Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines. <i>Irish Journal of Medical Science</i> , 2019 , 188, 169-172	1.9	8
218	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1472-1479	2.4	2
217	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019 , 95, 33-37	4.1	9
216	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019 , 95, 54-57	4.1	6
215	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. <i>Rheumatology</i> , 2019 , 58, 144-148	3.9	15
214	Inflammatory back pain criteria perform well in subset of patients with active axial psoriatic arthritis but not among patients with established axial disease. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1003-1004	2.4	9
213	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 990-995	4.1	26
212	Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. <i>MABs</i> , 2019 , 11, 116-128	6.6	54
211	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. <i>RMD Open</i> , 2018 , 4, e000582	5.9	25
210	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
209	Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 55, 271-294	12.3	34
208	Remission in psoriatic arthritis-where are we now?. <i>Rheumatology</i> , 2018 , 57, 1321-1331	3.9	8
207	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 654-665	5.3	32
206	Advanced musculoskeletal physiotherapy practice in Ireland: A National Survey. <i>Musculoskeletal Care</i> , 2018 , 16, 425-432	1.6	7
205	Advanced practice physiotherapy-led triage in Irish orthopaedic and rheumatology services: national data audit. <i>BMC Musculoskeletal Disorders</i> , 2018 , 19, 181	2.8	15

204	Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 73	5.7	20
203	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018 , 94, 17-25	4.1	8
202	Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity. <i>Arthritis and Rheumatology</i> , 2018 , 70, 396-407	9.5	32
201	Work Outcomes in Patients Who Stay at Work Despite Musculoskeletal Pain. <i>Journal of Occupational Rehabilitation</i> , 2018 , 28, 559-567	3.6	14
200	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 345-355	9.5	51
199	Opportunities and challenges in the treatment of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 440-452	5.3	7
198	Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?. <i>Rheumatology</i> , 2018 , 57, 2053-2059	3.9	0
197	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018 , 20, 242	5.7	17
196	Modifications of Cardiovascular Risk Scores, But Not Standard Risk Scores, Improve Identification of Asymptomatic Coronary Artery Disease in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 1329-1330	4.1	5
195	Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy. <i>Musculoskeletal Care</i> , 2017 , 15, 23-35	1.6	13
194	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1522-1528	4.1	66
193	Effects of targeted therapies on the bone in arthritides. <i>Autoimmunity Reviews</i> , 2017 , 16, 313-320	13.6	37
192	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 673-680	2.4	138
191	GRAPPA 2016 Project Report. <i>Journal of Rheumatology</i> , 2017 , 44, 706-710	4.1	1
190	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1550-1558	2.4	129
189	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017 , 44, 697-700	4.1	29
188	Early interventions to promote work participation in people with regional musculoskeletal pain: a systematic review and meta-analysis. <i>Clinical Rehabilitation</i> , 2017 , 31, 1466-1481	3.3	10
187	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 377, 1537-1550	59.2	297

186	Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 158	5.7	19
185	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1774-1779	2.4	36
184	A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2017 , 44, 1445-1452	4.1	9
183	The Effect of Anterior Uveitis and Previously Undiagnosed Spondyloarthritis: Results from the DUET Cohort. <i>Journal of Rheumatology</i> , 2017 , 44, 1347-1354	4.1	17
182	Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 270-276	2.2	21
181	Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 234-41	2.4	37
180	Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 155-62	2.4	73
179	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016 , 43, 965-9	4.1	22
178	Replication of a distinct psoriatic arthritis risk variant at the IL23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1417-8	2.4	5
177	Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discovery. <i>Proteomics - Clinical Applications</i> , 2016 , 10, 691-8	3.1	18
176	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , 2016 , 43, 979-85	4.1	2
175	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 291-304	5.3	84
174	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1060-71	9.5	485
173	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements. <i>Journal of Rheumatology</i> , 2016 , 43, 208-13	4.1	22
172	Psoriatic arthritis: complexities, comorbidities and implications for the clinic. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 405-16	5.1	22
171	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1034-42	2.4	44
170	Treatment of psoriatic arthritis 2016 , 85-99		
169	A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF- α treatment of psoriatic arthritis. <i>Proteomics - Clinical Applications</i> , 2016 , 10, 645-62	3.1	17

168	Improving recognition of spondyloarthropathy in primary care: an unmet need. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e19	2.4	
167	Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 318-9	8.1	3
166	Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions. <i>Journal of Rheumatology</i> , 2016 , 43, 463-4	4.1	14
165	Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry. <i>Rheumatology</i> , 2016 , 55, 891-6	3.9	12
164	Implications of the diversity of class I HLA associations in psoriatic arthritis. <i>Clinical Immunology</i> , 2016 , 172, 29-33	9	12
163	Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015 , 42, 2198-203	4.1	29
162	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1048-1051	4.1	6
161	Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis. <i>Clinical Rheumatology</i> , 2015 , 34, 1857-65	3.9	13
160	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1021-1026	4.1	8
159	A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1990-5	2.4	65
158	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015 , 6, 6046	17.4	103
157	Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1045-50	2.4	290
156	Profound reduction in hospital admissions and musculoskeletal surgical procedures for rheumatoid arthritis with concurrent changes in clinical practice (1995-2010). <i>Rheumatology</i> , 2015 , 54, 666-71	3.9	21
155	Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. <i>Arthritis Research and Therapy</i> , 2015 , 17, 115	5.7	126
154	Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 141	5.7	49
153	Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and management. <i>Current Rheumatology Reports</i> , 2015 , 17, 35	4.9	10
152	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1882-5	2.4	49
151	Peripheral joint involvement in psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S26-30	2.2	17

150	Sustained remission with etanercept tapering in early rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2014 , 371, 1781-92	59.2	141
149	Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. <i>Journal of Rheumatology</i> , 2014 , 41, 2277-85	4.1	38
148	Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 238-42	2.4	54
147	Inequities in access to biologic and synthetic DMARDs across 46 European countries. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 198-206	2.4	225
146	Patient involvement in outcome measures for psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2014 , 16, 418	4.9	27
145	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 6-16	2.4	308
144	High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. <i>Journal of Rheumatology</i> , 2014 , 41, 1357-65	4.1	107
143	Qualifying unmet needs and improving standards of care in psoriatic arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 1759-66	4.7	57
142	How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal study. <i>Arthritis Care and Research</i> , 2014 , 66, 1597-603	4.7	10
141	Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1206-11	4.1	12
140	Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014 , 41, 782-91	4.1	30
139	GRAPPA 2013 Annual Meeting, rheumatology updates: psoriatic arthritis (PsA) biomarker project, arthritis mutilans, PsA-peripheral spondyloarthritis epidemiology project. <i>Journal of Rheumatology</i> , 2014 , 41, 1244-8	4.1	5
138	Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. <i>Arthritis Care and Research</i> , 2014 , 66, 1410-6	4.7	18
137	Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. <i>Journal of Rheumatology</i> , 2014 , 41, 1212-7	4.1	69
136	Tumor necrosis factor inhibition modulates thrombospondin-1 expression in human inflammatory joint disease through altered NR4A2 activity. <i>American Journal of Pathology</i> , 2013 , 183, 1243-1257	5.8	20
135	Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. <i>Rheumatology</i> , 2013 , 52, 1572-82	3.9	35
134	Th17 and Th22 cells in psoriatic arthritis and psoriasis. <i>Arthritis Research and Therapy</i> , 2013 , 15, R136	5.7	158
133	Exercise and manual physiotherapy arthritis research trial (EMPART) for osteoarthritis of the hip: a multicenter randomized controlled trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2013 , 94, 302-14	2.8	68

132	Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 653-62	4.1	21
131	High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 736-40	2.4	198
130	Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1504-9		52
129	Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1224-31		56
128	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 986-91	2.4	192
127	Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. <i>Arthritis Research and Therapy</i> , 2013 , 15, R221	5.7	28
126	Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeans. <i>PLoS ONE</i> , 2013 , 8, e66456	3.7	24
125	Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis. <i>PLoS ONE</i> , 2013 , 8, e76292	3.7	23
124	Classification and monitoring of disease activity 2013 , 24-34		
123	Vitamin D and its emerging role in immunopathology. <i>Clinical Rheumatology</i> , 2012 , 31, 199-202	3.9	30
122	A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 225-30	2.4	53
121	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 358-62	2.4	52
120	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 319-26	2.4	201
119	Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 313-4	2.4	11
118	Pathogenetic overview of psoriatic disease. <i>Journal of rheumatology Supplement, The</i> , 2012 , 89, 7-10		14
117	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012 , 44, 1341-8	36.3	681
116	HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1134-44		144
115	Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1035-45		73

114	Vitamin D deficiency: subclinical and clinical consequences on musculoskeletal health. <i>Current Rheumatology Reports</i> , 2012 , 14, 286-93	4.9	27
113	Pulmonary fibrosis in systemic sclerosis: association with myocardial fibrosis. <i>Journal of Thoracic Imaging</i> , 2012 , 27, 44-50	5.6	3
112	GRAPPA Responder Index Project (GRACE): a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , 2012 , 39, 2196-7	4.1	7
111	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1350-4	2.4	31
110	Biomarkers of radiographic progression in psoriatic arthritis: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , 2012 , 39, 2189-92	4.1	9
109	The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort. <i>Value in Health</i> , 2011 , 14, 921-7	3.3	6
108	Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R7	5.7	31
107	Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease. <i>PLoS ONE</i> , 2011 , 6, e27182	3.7	9
106	Responsiveness of physical function outcomes following physiotherapy intervention for osteoarthritis of the knee: an outcome comparison study. <i>Physiotherapy</i> , 2011 , 97, 302-8	3	41
105	Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNF therapy medication. <i>BMC Musculoskeletal Disorders</i> , 2011 , 12, 11	2.8	3
104	Clinical image: keratitis in reactive arthritis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2522		9
103	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1016-9	2.4	60
102	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1641-4	2.4	93
101	Composite Measures in Psoriatic Arthritis: a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , 2011 , 38, 540-5	4.1	21
100	Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. <i>Journal of Rheumatology</i> , 2011 , 38, 1496-501	4.1	30
99	Development of a preliminary composite disease activity index in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 272-7	2.4	133
98	Osteoarthritis: 119. The Effectiveness of Exercise Therapy with and without Manual Therapy for Hip Osteoarthritis: A Multicentre Randomised Controlled Trial. <i>Rheumatology</i> , 2011 , 50, iii87-iii90	3.9	
97	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. <i>Nature Genetics</i> , 2010 , 42, 996-9	36.3	294

96	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010 , 42, 985-90	36.3	773
95	A qualitative study of work participation in early rheumatoid arthritis. <i>International Journal of Therapy and Rehabilitation</i> , 2010 , 17, 24-33	0.4	14
94	Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 706-14	2.4	34
93	Composite measures in psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 453-61	4.1	21
92	Synovial tissue hypoxia and inflammation in vivo. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1389-95	2.4	148
91	Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 1386-94	4.1	93
90	Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 448-52	4.1	14
89	Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 462-7	4.1	10
88	Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. <i>Journal of Immunology</i> , 2010 , 184, 6427-37	5.3	82
87	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2199-203	2.4	35
86	Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 394-9	2.4	101
85	Remission in psoriatic arthritis: is it possible and how can it be predicted?. <i>Arthritis Research and Therapy</i> , 2010 , 12, R94	5.7	59
84	Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. <i>Pharmacoeconomics</i> , 2010 , 28, 477-87	4.4	40
83	Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. <i>Rheumatology International</i> , 2010 , 30, 1571-80	3.6	6
82	Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice. <i>Current Rheumatology Reports</i> , 2010 , 12, 264-71	4.9	2
81	Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, 401-4	2.2	15
80	Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. <i>Journal of Rheumatology</i> , 2009 , 36, 1792-9	4.1	30
79	Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. <i>Journal of Rheumatology</i> , 2009 , 36, 1785-91	4.1	35

78	Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. <i>Journal of Rheumatology</i> , 2009 , 36, 1769-84	4.1	15
77	Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. <i>Journal of Rheumatology</i> , 2009 , 36, 1800-2	4.1	89
76	Exercise and manual physiotherapy arthritis research trial (EMPART): a multicentre randomised controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2009 , 10, 9	2.8	12
75	Constitutional trisomy 8 and Behçet syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2009 , 149A, 982-6	2.5	20
74	Serum levels of tissue inhibitor of metalloproteinase-1 and periarticular bone loss in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009 , 28, 285-91	3.9	10
73	Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. <i>Molecular Immunology</i> , 2009 , 46, 3345-57	4.3	43
72	Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. <i>Arthritis Research and Therapy</i> , 2009 , 11, R113	5.7	128
71	Psoriatic arthritis: from pathogenesis to therapy. <i>Arthritis Research and Therapy</i> , 2009 , 11, 214	5.7	77
70	Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-alpha inhibition. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 300-10	4.3	28
69	Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry. <i>Clinical Rheumatology</i> , 2008 , 27, 763-6	3.9	7
68	Biological biomarkers in psoriatic disease. A review. <i>Journal of Rheumatology</i> , 2008 , 35, 1443-8	4.1	15
67	Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2919-28		42
66	Filaggrin null alleles are not associated with psoriasis. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 1878-82	4.3	36
65	A role for type 1alpha corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. <i>American Journal of Pathology</i> , 2007 , 170, 1121-33	5.8	14
64	Inpatient and outpatient rehabilitation for patients with rheumatoid arthritis: a clinical and economic assessment. <i>Journal of Medical Economics</i> , 2007 , 10, 515-528	2.4	1
63	Pathogenesis of Psoriatic Arthritis 2007 , 48-60		1
62	Immunohistochemistry of the inflamed synovium. <i>Methods in Molecular Medicine</i> , 2007 , 135, 47-63		4
61	Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. <i>Journal of Rheumatology</i> , 2007 , 34, 620-2	4.1	45

60	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 1167-70	4.1	144
59	Psoriatic arthritis: one or more diseases?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006 , 20, 435-50	5.3	21
58	Spondyloarthropathy: disease at the crossroads of immunity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006 , 20, 949-67	5.3	12
57	Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. <i>Arthritis and Rheumatism</i> , 2006 , 54, 105-14		121
56	Temporal expression pattern of Duffy antigen in rheumatoid arthritis: up-regulation in early disease. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2022-6		16
55	Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1795-804		57
54	Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3152-62		61
53	Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 1003-12	4.5	86
52	Synovial tissue inflammation in early and late osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 1263-7	2.4	612
51	Psoriatic arthritis synovial histopathology: commentary on the article by Kruithof and colleagues. <i>Arthritis Research</i> , 2005 , 7, 124-5		3
50	Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. <i>European Journal of Immunology</i> , 2005 , 35, 1347-59	6.1	202
49	Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. <i>Journal of Immunology</i> , 2005 , 175, 555-65	5.3	45
48	Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1393-8	2.4	55
47	Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. <i>Journal of Immunology</i> , 2004 , 172, 1935-44	5.3	61
46	Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective. <i>Current Rheumatology Reports</i> , 2004 , 6, 292-8	4.9	25
45	Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1132-45		27
44	Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1781-7		70
43	Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1788-99		119

42	Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3286-95		63
41	Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?. <i>Arthritis Research</i> , 2004 , 6, R563-6		50
40	Suprascapular nerve block (using bupivacaine and methylprednisolone acetate) in chronic shoulder pain. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 400-6	2.4	98
39	The influence of alpha1-acid glycoprotein on collagenase-3 activity in early rheumatoid arthritis. <i>Biomedical Chromatography</i> , 2003 , 17, 361-4	1.7	9
38	Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1408-13		113
37	Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1676-85		97
36	Quality of life, social support, and knowledge of disease in women with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 49, 221-7		37
35	Identification of Naf1/ABIN-1 among TNF-alpha-induced expressed genes in human synoviocytes using oligonucleotide microarrays. <i>FEBS Letters</i> , 2003 , 551, 8-12	3.8	42
34	Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. <i>Drugs</i> , 2003 , 63 Suppl 1, 31-6	12.1	16
33	Preliminary observations on the influence of rheumatoid alpha-1-acid glycoprotein on collagen fibril formation. <i>Biomedical Chromatography</i> , 2002 , 16, 332-42	1.7	12
32	Corticotropin-releasing hormone signaling in synovial tissue vascular endothelium is mediated through the cAMP/CREB pathway. <i>Annals of the New York Academy of Sciences</i> , 2002 , 966, 119-30	6.5	28
31	Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5'Smonophosphate response element-binding protein in rheumatoid arthritis synovial tissue. <i>Journal of Immunology</i> , 2002 , 168, 2979-87	5.3	92
30	Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 726-9	2.4	49
29	Disease mechanisms in psoriasis and psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2001 , 3, 419-27	4.9	7
28	Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 782-93		78
27	Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1744-53		97
26	Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 alpha corticotropin-releasing hormone receptor. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1761-7		49
25	Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2263-74		111

24	Psoriatic arthritis--an enthesopathy-based disorder? Comment on the article by McGonagle et al. <i>Arthritis and Rheumatism</i> , 2000 , 43, 712-4		3
23	Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. <i>Arthritis Research</i> , 2000 , 2, 142-4		107
22	Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. <i>Rheumatology</i> , 1999 , 38, 34-42	3.9	87
21	Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. <i>Annals of the Rheumatic Diseases</i> , 1999 , 58, 493-9	2.4	38
20	Tuberculosis of the wrist. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2724-6		10
19	Multidisciplinary patient care in rheumatoid arthritis: evolving concepts in nursing practice. <i>Best Practice and Research in Clinical Rheumatology</i> , 1999 , 13, 661-74	5.3	9
18	Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 1998 , 41, 180-2		39
17	Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. <i>Arthritis and Rheumatism</i> , 1998 , 41, 663-9		99
16	Ultrasound guided injection of recalcitrant plantar fasciitis. <i>Annals of the Rheumatic Diseases</i> , 1998 , 57, 383-4	2.4	60
15	Comparison of the accuracy of steroid placement with clinical outcome in patients with shoulder symptoms. <i>Annals of the Rheumatic Diseases</i> , 1997 , 56, 59-63	2.4	224
14	Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 1997 , 9, 295-301	5.3	8
13	Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 115-24		408
12	Synovial membrane cellularity and vascularity. <i>Annals of the Rheumatic Diseases</i> , 1995 , 54, 511-5	2.4	52
11	The significance of fat and muscle areas in the lumbar paraspinal space: a CT study. <i>Journal of Computer Assisted Tomography</i> , 1994 , 18, 275-8	2.2	30
10	Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 893-900		205
9	Lymphedema of the upper limb in patients with psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1993 , 22, 350-6	5.3	34
8	Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis. <i>American Journal of Cardiology</i> , 1993 , 71, 1337-40	3	50
7	Synovial vascularity is increased in rheumatoid arthritis: comment on the article by Stevens et al. <i>Arthritis and Rheumatism</i> , 1992 , 35, 1540-1		14

6	Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1991 , 50, 792-6	2.4	91
5	Prospective study of the evolution of Raynaud's phenomenon. <i>American Journal of Medicine</i> , 1988 , 84, 718-26	2.4	60
4	Effects of joint lavage on knee synovitis in rheumatoid arthritis. <i>Rheumatology</i> , 1985 , 24, 6-10	3.9	13
3	Poor long-term results from low-dose methotrexate therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1984 , 27, 599-600		11
2	Nicotinic acid inhibition of uricase. <i>Irish Journal of Medical Science</i> , 1969 , 8, 531-4	1.9	1
1	Urease in the gastric mucosa and its increase after a meat diet, soya bean flour diet or urogastone infections. <i>Nature</i> , 1946 , 158, 305	50.4	17